Download Gilead Submits New Drug Application to US Food and

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of
Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
October 28, 2015 5:53 PM ET
-- If Approved, Combination Would Be First All-Oral, Pan-Genotypic Single-Tablet Regimen for Chronic HCV
Infection --- Filing is Company’s Third in Three Years for a New HCV Medicine -FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 28, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that
it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational,
once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi®
in December 2013, and velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic
genotype 1-6 hepatitis C virus (HCV) infection. The NDA is supported by clinical studies exploring the use of 12 weeks
of SOF/VEL for patients with genotype 1-6 HCV infection, including patients with compensated cirrhosis and 12 weeks
of SOF/VEL with ribavirin for patients with decompensated cirrhosis.
“As the first fixed-dose combination of two pan-genotypic, direct-acting antivirals, SOF/VEL represents an important
step forward in the treatment of patients with hepatitis C,” said Norbert Bischofberger, PhD, Executive Vice President of
Research and Development and Chief Scientific Officer at Gilead. “Genotype 1 is the most prevalent form of HCV in the
United States, but worldwide, more than half of people living with HCV are infected with other genotypes. SOF/VEL
complements our current HCV portfolio of Sovaldi and Harvoni, offering high cure rates and the potential to simplify
treatment and eliminate the need for HCV genotype testing.”
The FDA has assigned SOF/VEL a Breakthrough Therapy designation, which is granted to investigational medicines that
may offer major advances in treatment over existing options. The NDA for SOF/VEL is supported by data from four
Phase 3 ASTRAL trials, which evaluated the fixed-dose combination in hepatitis C genotypes 1-6. Of the 1,035 patients
treated with SOF/VEL for 12 weeks in the ASTRAL-1, ASTRAL-2 and ASTRAL-3 studies, 1,015 (98 percent) achieved
the primary efficacy endpoint of SVR12. The ASTRAL-4 study randomized 267 patients with decompensated cirrhosis
(Child-Pugh class B) to receive 12 weeks of SOF/VEL with or without ribavirin (RBV), or 24 weeks of SOF/VEL. Those
who received SOF/VEL plus RBV for 12 weeks achieved an SVR12 rate of 94 percent, while those who received SOF/VEL
for 12 weeks and 24 weeks achieved SVR12 rates of 83 percent and 86 percent, respectively.
Patients treated with SOF/VEL for 12 weeks in ASTRAL-1, ASTRAL-2 and ASTRAL-3 had similar adverse events
compared with placebo-treated patients in ASTRAL-1. The most common adverse events were headache, fatigue and
nausea. The most common adverse events in ASTRAL-4 were fatigue, nausea and headache.
Gilead plans to submit a regulatory application for approval of SOF/VEL in the European Union by the end of the year.
The SOF/VEL fixed-dose combination is an investigational product and its safety and efficacy have not been established.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in
areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening
diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995 that are subject to risks, uncertainties and other factors, including the risk that FDA may not approve the
Page 1/2
SOF/VEL fixed-dose combination, and that any marketing approvals, if granted, may have significant limitations on its
use. In addition, Gilead may be unable to file for regulatory approval of SOF/VEL in other geographies in the currently
anticipated timelines. Further, additional clinical studies of SOF/VEL may produce unfavorable results. As a result, Gilead
may not be able to successfully commercialize SOF/VEL. These risks, uncertainties and other factors could cause actual
results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form
10-Q for the quarter ended June 30, 2015, as filed with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such
forward-looking statements.
U.S. full prescribing information for Sovaldi and Harvoni is available at www.gilead.com.
Sovaldi and Harvoni are registered trademarks of Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter
(@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028006842/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Investors:
Patrick O’Brien, 650-522-1936
or
Media:
Cara Miller, 650-522-1616
Page 2/2